ImmunoPrecise Antibodies Income Statement

Financials in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021	2016 - 2020
Revenue	24.52	24.52	20.67	19.36	17.91	Upgrade
Revenue Growth (YoY)	0.01%	18.64%	6.72%	8.11%	27.41%	Upgrade
Cost of Revenue	10.97	12.47	9.1	8.38	6.51	Upgrade
Gross Profit	13.55	12.05	11.56	10.98	11.4	Upgrade
Selling, General & Admin	19.03	19.14	18.19	18.06	10.59	Upgrade
Research & Development	4.94	4.04	14.1	7.66	1.97	Upgrade
Operating Expenses	25.92	26.15	36.71	27.73	18.06	Upgrade
Operating Income	-12.38	-14.09	-25.14	-16.75	-6.65	Upgrade
Interest Expense	-0.29	-0.02	-0.03	-0.09	-0.64	Upgrade
Interest & Investment Income	-	0.02	0.12	0.28	0.28	Upgrade
Currency Exchange Gain (Loss)	-0.59	0.09	0.23	0.63	-1.23	Upgrade
Other Non Operating Income (Expenses)	0.18	0.33	0.33	0.08	-0.22	Upgrade
EBT Excluding Unusual Items	-13.08	-13.67	-24.49	-15.85	-8.47	Upgrade
Merger & Restructuring Charges	-	-	-0.8	-	-	Upgrade
Impairment of Goodwill	-	-11.16	-2.46	-	-	Upgrade
Asset Writedown	-21.18	-3.87	-	-	-	Upgrade
Other Unusual Items	-	-	-	-	2.47	Upgrade
Pretax Income	-34.27	-28.7	-27.75	-15.85	-6	Upgrade
Income Tax Expense	-4.03	-2.59	-1.19	0.86	1.35	Upgrade
Net Income	-30.23	-26.12	-26.56	-16.71	-7.34	Upgrade
Net Income to Common	-30.23	-26.12	-26.56	-16.71	-7.34	Upgrade
Shares Outstanding (Basic)	33	26	25	20	16	Upgrade
Shares Outstanding (Diluted)	33	26	25	20	16	Upgrade
Shares Change (YoY)	30.23%	2.97%	26.46%	19.51%	20.88%	Upgrade
EPS (Basic)	-0.91	-1.02	-1.07	-0.85	-0.45	Upgrade
EPS (Diluted)	-0.91	-1.02	-1.07	-0.85	-0.45	Upgrade
Free Cash Flow	-7.21	-4.58	-21.33	-10.99	-2.03	Upgrade
Free Cash Flow Per Share	-0.22	-0.18	-0.86	-0.56	-0.12	Upgrade
Gross Margin	55.25%	49.16%	55.95%	56.72%	63.67%	Upgrade
Operating Margin	-50.47%	-57.48%	-121.67%	-86.49%	-37.14%	Upgrade
Profit Margin	-123.30%	-106.51%	-128.53%	-86.29%	-40.98%	Upgrade
Free Cash Flow Margin	-29.40%	-18.68%	-103.21%	-56.74%	-11.32%	Upgrade
EBITDA	-9.31	-10.37	-18.46	-12.98	-4.6	Upgrade
EBITDA Margin	-37.98%	-42.30%	-89.32%	-67.03%	-25.66%	Upgrade
D&A For EBITDA	3.06	3.72	6.69	3.77	2.06	Upgrade
EBIT	-12.38	-14.09	-25.14	-16.75	-6.65	Upgrade
EBIT Margin	-50.47%	-57.48%	-121.67%	-86.49%	-37.14%	Upgrade
Advertising Expenses	-	-	-	-	0.69	Upgrade

Updated Jul 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q